HTLF Bank Takes Position in Gilead Sciences, Inc. (NASDAQ:GILD)

HTLF Bank acquired a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm acquired 3,120 shares of the biopharmaceutical company’s stock, valued at approximately $253,000.

Several other hedge funds have also added to or reduced their stakes in GILD. PCA Investment Advisory Services Inc. acquired a new stake in Gilead Sciences during the 2nd quarter worth $25,000. OFI Invest Asset Management bought a new position in Gilead Sciences during the 3rd quarter worth about $26,000. Tompkins Financial Corp increased its holdings in Gilead Sciences by 223.1% during the 3rd quarter. Tompkins Financial Corp now owns 349 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 241 shares in the last quarter. Fortitude Family Office LLC bought a new position in Gilead Sciences during the 4th quarter worth about $29,000. Finally, Rakuten Securities Inc. bought a new position in Gilead Sciences during the 4th quarter worth about $33,000. Institutional investors and hedge funds own 83.67% of the company’s stock.

Gilead Sciences Trading Up 0.9 %

Gilead Sciences stock opened at $66.76 on Friday. Gilead Sciences, Inc. has a 52 week low of $65.90 and a 52 week high of $87.86. The company has a debt-to-equity ratio of 1.08, a quick ratio of 1.27 and a current ratio of 1.43. The stock has a market capitalization of $83.12 billion, a P/E ratio of 14.84, a PEG ratio of 0.92 and a beta of 0.19. The stock has a 50-day simple moving average of $71.96 and a 200 day simple moving average of $76.56.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Tuesday, February 6th. The biopharmaceutical company reported $1.72 EPS for the quarter, missing analysts’ consensus estimates of $1.76 by ($0.04). Gilead Sciences had a return on equity of 38.85% and a net margin of 20.89%. The business had revenue of $7.12 billion for the quarter, compared to the consensus estimate of $7.10 billion. During the same quarter in the previous year, the business posted $1.67 EPS. The company’s revenue for the quarter was down 3.7% on a year-over-year basis. Analysts expect that Gilead Sciences, Inc. will post 6.55 earnings per share for the current year.

Gilead Sciences Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Thursday, March 28th. Shareholders of record on Friday, March 15th were given a dividend of $0.77 per share. The ex-dividend date of this dividend was Thursday, March 14th. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.75. This represents a $3.08 annualized dividend and a yield of 4.61%. Gilead Sciences’s dividend payout ratio (DPR) is 68.44%.

Analyst Ratings Changes

A number of equities analysts have issued reports on GILD shares. Oppenheimer reiterated an “outperform” rating and set a $105.00 target price on shares of Gilead Sciences in a report on Friday. Barclays lowered their target price on Gilead Sciences from $85.00 to $80.00 and set an “equal weight” rating for the company in a report on Monday, February 12th. StockNews.com cut Gilead Sciences from a “strong-buy” rating to a “buy” rating in a report on Friday. UBS Group decreased their price objective on Gilead Sciences from $81.00 to $75.00 and set a “neutral” rating for the company in a report on Wednesday. Finally, Cantor Fitzgerald decreased their price objective on Gilead Sciences from $80.00 to $78.00 and set a “neutral” rating for the company in a report on Wednesday, February 7th. One investment analyst has rated the stock with a sell rating, nine have given a hold rating and six have issued a buy rating to the company’s stock. According to MarketBeat, Gilead Sciences has a consensus rating of “Hold” and a consensus target price of $84.71.

Insiders Place Their Bets

In other Gilead Sciences news, insider Merdad Parsey sold 2,000 shares of the firm’s stock in a transaction that occurred on Monday, April 1st. The shares were sold at an average price of $72.96, for a total transaction of $145,920.00. Following the completion of the sale, the insider now directly owns 96,304 shares in the company, valued at $7,026,339.84. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Company insiders own 0.16% of the company’s stock.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.